Viking Therapeutics: A Promising Pipeline Tempered by Tolerability Questions

Viking Therapeutics finds itself at a pivotal juncture, navigating a complex landscape with a portfolio of promising metabolic disease treatments. The company’s recent clinical data presents a compelling yet nuanced picture for investors.

Clinical Progress and Investor Scrutiny

Recent Phase 2 results for the oral formulation of its obesity drug candidate, VK2735, delivered a strong efficacy signal. Data demonstrated that patients in the highest dose cohort achieved an average weight reduction of 12.2% over a 13-week treatment period. These statistically significant results underscore the drug’s potential therapeutic value.

However, investor enthusiasm has been tempered by a notable rate of study discontinuations. A significant number of participants withdrew from the trial due to gastrointestinal adverse events, raising questions about the drug’s tolerability Read more...

US92686J1060 | VIKING | boerse | 68165703 |